Glumetinib is primarily used in the field of oncology as a targeted therapy for non-small cell lung cancer (NSCLC). It functions as a MET tyrosine kinase inhibitor, which helps in blocking the activity of the MET protein that is often overexpressed or mutated in certain types of cancer. By inhibiting this protein, Glumetinib can effectively slow down or stop the growth and spread of cancer cells. This makes it a valuable option for patients whose cancers are driven by MET alterations, providing a more personalized treatment approach. Clinical trials have shown promising results in improving progression-free survival and overall response rates in patients with MET-dysregulated NSCLC. Additionally, its targeted nature often results in fewer side effects compared to traditional chemotherapy, enhancing the quality of life for patients undergoing treatment.